Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Lexaria Bioscience Corp. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +1 vs. Q2 2023
- Shares held
- 1.77M
- +878.8K (+98.4%) vs. Q2 2023
- Total value
- $1.77M
- +$1.12M (+171.8%) vs. Q2 2023
- New holders
- 3
- 2 more added
- Sold out
- 2
- 4 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LEXX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $920.0K |
| Q1 2026 | 28 | $1.17M |
| Q4 2025 | 21 | $1.05M |
| Q3 2025 | 25 | $1.63M |
| Q2 2025 | 21 | $2.00M |
| Q1 2025 | 22 | $2.12M |
| Q4 2024 | 25 | $3.03M |
| Q3 2024 | 27 | $3.25M |
| Q2 2024 | 28 | $5.72M |
| Q1 2024 | 25 | $3.23M |
| Q4 2023 | 20 | $1.49M |
| Q3 2023 | 15 | $1.77M |
| Q2 2023 | 14 | $651.4K |
| Q1 2023 | 17 | $1.85M |
| Q4 2022 | 16 | $1.71M |
| Q3 2022 | 16 | $1.68M |
| Q2 2022 | 16 | $1.67M |
| Q1 2022 | 12 | $1.41M |
| Q4 2021 | 13 | $1.85M |
| Q3 2021 | 11 | $2.83M |
| Q2 2021 | 10 | $2.93M |
| Q1 2021 | 9 | $1.78M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Lexaria Bioscience Corp.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 889,272 | $889.2K | 0.03% | +889,272 | New |
| Invenomic Capital Management LP | 764,332 | $764.3K | 0.03% | −2,241−0.3% | Reduced |
| Geode Capital Management, LLC | 47,416 | $47.0K | 0.00% | −1,421−2.9% | Reduced |
| Vanguard Group Inc | 33,329 | $33.3K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 12,900 | $13.0K | 0.00% | +2,200+20.6% | Added |
| Two Sigma Securities, LLC | 10,545 | $10.5K | 0.00% | +10,545 | New |
| Tower Research Capital LLC (TRC) | 8,330 | $8.33K | 0.00% | −2,621−23.9% | Reduced |
| 1832 Asset Management L.P. | 2,686 | $2.69K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 1,086 | $1.09K | 0.00% | +15+1.4% | Added |
| Advisor Group Holdings, Inc. | 650 | $649 | 0.00% | −1,393−68.2% | Reduced |
| Aspire Private Capital, LLC | 400 | $399 | 0.00% | 00.0% | Unchanged |
| Farther Finance Advisors, LLC | 166 | $166 | 0.00% | 00.0% | Unchanged |
| Toronto Dominion Bank | 13 | $13 | 0.00% | 00.0% | Unchanged |
| Gables Capital Management Inc. | 13 | $13 | 0.00% | +13 | New |
| Royal Bank of Canada | 394 | $0 | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −15,426−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −99−100.0% | Sold out |